Want to see AU:NEU full AI Analyst Report?
Top Page
Neuren Pharmaceuticals Limited
(Sydney:NEU)
Select Model
Select Model
Rating:74Outperform
Price Target:
AU$25.00
▲(22.25% Upside)
Action:Upgraded
Date:08/26/26
The score is primarily supported by strong financial quality for the sector (high profitability and zero debt) and a favorable earnings update (raised commercial guidance, strong cash, and a new dividend framework). Technicals also point to a solid uptrend. These positives are moderated by a very high P/E and ongoing volatility/uncertainty in revenue and cash flow consistency, plus execution and regulatory timing risks in the pipeline.
Positive Factors
Debt-Free Balance Sheet
A large cash balance and debt-free structure give Neuren the capacity to fund NNZ-2591 development and corporate needs internally, reducing dilution risk and preserving flexibility through clinical and regulatory cycles.
Negative Factors
Revenue Volatility
Despite high margins and recent profitability, uneven revenue performance reduces visibility into earnings durability. Dependence on partner milestones and commercial timing may produce fluctuations that complicate long-term financial planning.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
A large cash balance and debt-free structure give Neuren the capacity to fund NNZ-2591 development and corporate needs internally, reducing dilution risk and preserving flexibility through clinical and regulatory cycles.
Read all positive factors
Neuren Pharmaceuticals Limited (NEU) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.58B
Dividend Yield0%
Average Volume (3M)638.53K
Price to Earnings (P/E)128.4
Beta (1Y)2.71
Revenue Growth-68.00%
EPS Growth-86.31%
CountryAU
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.16
Shares Outstanding126,773,980
10 Day Avg. Volume641,342
30 Day Avg. Volume638,531
Financial Highlights & Ratios
PEG Ratio-0.99
Price to Book (P/B)7.05
Price to Sales (P/S)36.92
P/FCF Ratio19.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$26.25Price Target Upside28.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.35
Revenue Forecast (FY)AU$122.02M
Neuren Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 year...
How the Company Makes Money
Neuren makes money primarily through out-licensing its drug programs and earning payments tied to its partners’ development and commercial performance. For trofinetide/DAYBUE, Neuren licensed rights to Acadia Pharmaceuticals and receives revenue v...
Neuren Pharmaceuticals Limited Earnings Call Summary
Earnings Call Date:Aug 25, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Feb 24, 2027
Earnings Call Sentiment Positive
The call conveyed strong commercial and financial momentum driven by DAYBUE (cash USD 287M, H1 royalties USD 23M, upgraded guidance and European approval), initiation of a fully franked dividend program, and meaningful progress on NNZ-2591 (Koala Phase III recruitment momentum, Priority Review Voucher value). Challenges include a regulatory-driven delay for HIE (juvenile animal study), remaining execution risk and timeline uncertainty for the placebo-controlled Koala trial (two co-primary endpoints and enrollment duration), and some disclosure gaps on European milestone detail. On balance the positives — robust cash position, confirmed funding for programs, recurring royalties, tangible commercial milestones and increasing product uptake — materially outweigh the setbacks and schedule risks.Positive Updates
Strong cash position
Cash of USD 287 million at 30 June 2026, providing full funding for all NNZ-2591 programs and supporting R&D spend without need for near-term capital raises.
Negative Updates
HIE IND timing delayed by juvenile animal study
FDA requested an additional juvenile animal toxicology study for the HIE program; protocol submitted in mid-May but feedback still outstanding — the 3-month study pushes IND filing from Q4 2026 into H1 2027, creating a program timing delay.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong cash position
Cash of USD 287 million at 30 June 2026, providing full funding for all NNZ-2591 programs and supporting R&D spend without need for near-term capital raises.
Read all positive updates
Company Guidance
Management provided detailed numeric guidance and milestones: cash of $287M at 30 June; H1 royalty income ~US$23M with Acadia‑based full‑year royalty guidance of US$53–56M implying an available dividend pool of US$48.0–51.6M for the year; a new semi‑annual dividend policy paying 70–100% of that pool (initially set at 90%), delivering a fully franked interim dividend of $0.15 per share payable 7 Oct (franking credits ≈$76M); DAYBUE/Acadia raised global sales guidance by US$20M to US$480–510M (forecast US$700M in 2028) with STIX adoption at 40% of patients as of 30 Jun; commercial milestones include US$50M for calendar‑year North America sales >US$500M, US$35M for first commercial sale in Europe and US$15M for first Japan sale, and Neuren holds 100% of the Priority Review Voucher right (comparable recent voucher sale US$215M); R&D spend was US$27.4M in H1 (corporate & admin ~US$3M, interest income US$5.6M) and total PMS program cost to NDA remains guided at US$80–90M; Koala Phase III is randomized 160 children (1:1) with a 13‑week placebo‑controlled primary endpoint and 12‑month open‑label extension, 15 sites activated (target 20–24), 8 sites ready for the OLE, >100 referrals and 15 patients in screening with the trial powered 90% for the Vineland caregiver endpoint and an informal enrollment benchmark comparable to Acadia’s ~2‑year LAVENDER timeline; HIE juvenile‑tox study is ~3 months (pushing the IND into H1 next year); and a Type B face‑to‑face FDA meeting for Pitt Hopkins is scheduled for October with a patient‑focused FDA meeting in November.Neuren Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
88
Very Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.51M | 64.63M | 213.24M | 231.93M | 14.55M | 3.20M |
| Gross Profit | 69.49M | 64.61M | 213.22M | 205.17M | 14.54M | 3.19M |
| EBITDA | 13.87M | 22.05M | 175.57M | 199.26M | -670.00K | -10.98M |
| Net Income | 20.26M | 30.44M | 142.04M | 157.08M | 184.00K | -7.79M |
Balance Sheet | ||||||
| Total Assets | 340.62M | 342.86M | 409.71M | 247.97M | 43.27M | 40.06M |
| Cash, Cash Equivalents and Short-Term Investments | 286.54M | 296.12M | 222.24M | 228.54M | 40.18M | 36.78M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.24M | 4.41M | 45.80M | 42.76M | 1.68M | 803.00K |
| Stockholders Equity | 333.38M | 338.45M | 363.90M | 205.21M | 41.59M | 39.25M |
Cash Flow | ||||||
| Free Cash Flow | 5.08M | 125.39M | -11.28M | 184.88M | 3.58M | -9.98M |
| Operating Cash Flow | 5.12M | 125.42M | -11.27M | 184.93M | 3.60M | -9.97M |
| Investing Cash Flow | 16.38M | -88.01M | 4.13M | -211.49M | -19.00K | -10.00K |
| Financing Cash Flow | 2.83M | -33.22M | -8.78M | 3.62M | -2.00K | 22.18M |
Neuren Pharmaceuticals Limited Technical Analysis
Neutral
20.45
Price Trends
19.32
Positive
16.14
Positive
15.88
Positive
Market Momentum
0.19
Positive
48.16
Neutral
25.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NEU, the sentiment is Neutral. The current price of 20.45 is below the 20-day moving average (MA) of 21.92, above the 50-day MA of 19.32, and above the 200-day MA of 15.88, indicating a neutral trend. The MACD of 0.19 indicates Positive momentum. The RSI at 48.16 is Neutral, neither overbought nor oversold. The STOCH value of 25.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:NEU.
Neuren Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.58B | 128.43 | 6.03% | 0.00% | -68.00% | -86.31% | |
55 Neutral | AU$2.45B | -42.13 | -10.31% | ― | ― | 39.63% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$198.79M | -11.04 | -103.42% | ― | ― | 5.88% | |
46 Neutral | AU$23.77M | -4.39 | -30.02% | ― | ― | -10.32% |
* Healthcare Sector Average
AU:NEU
Neuren Pharmaceuticals Limited
20.33
-0.47
-2.26%
AU:ACW
Actinogen Medical
0.05
0.03
96.30%
AU:ZLD
Zelira Therapeutics
0.50
0.13
33.33%
AU:PYC
PYC Therapeutics Limited
2.49
1.26
102.44%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.06
-0.11
-64.12%
Neuren Pharmaceuticals Limited Corporate Events
Neuren Pharmaceuticals Declares Interim Dividend for June 2026 Half
Aug 26, 2026
Neuren Pharmaceuticals Limited has declared a fully franked interim dividend of AUD 0.15 per ordinary share, reflecting the company’s performance over the six‑month period ended 30 June 2026. The distribution will follow the ASX timeta...
Neuren launches first dividend as DAYBUE royalties and rare-disease pipeline gather pace
Aug 26, 2026
Neuren Pharmaceuticals has launched its first-ever dividend program, underpinned by rapidly growing royalty income from Rett syndrome drug DAYBUE, and declared a fully franked interim dividend of A$0.15 per share for the first half of 2026. The po...
Neuren lifts revenue, trims profit as R&D surge underpins first dividend
Aug 26, 2026
Neuren Pharmaceuticals reported an 8% rise in half-year revenue to A$42.7 million, driven largely by a 29% increase in U.S.-dollar royalty income from DAYBUE as uptake grew in the U.S. and through named patient programs abroad. However, profit aft...
Neuren Set for European Windfall as Rett Drug DAYBU Wins EU Approval
Aug 24, 2026
Neuren Pharmaceuticals’ exclusive licensee, Acadia Pharmaceuticals, has secured European Commission marketing authorisation for DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older, marking t...
Neuren to Brief Investors on H1 2026 Results as Rare Neurology Pipeline Advances
Aug 21, 2026
Neuren Pharmaceuticals will host an investor webinar on 26 August 2026 at 11:00 AM AEST to discuss its financial results for the first half of 2026, with participants able to submit questions before or during the session. The update comes as Neure...
Neuren lifts royalty outlook as DAYBUE sales hit record and global rollout advances
Aug 5, 2026
Neuren Pharmaceuticals reported strong second-quarter performance driven by its partner Acadia’s record DAYBUE® net sales of US$125 million, a 30% year-on-year increase and the highest quarterly result since launch. The growth was large...
Neuren deepens rare disease push as Phase 3 PMS trial gains momentum
Jul 24, 2026
Neuren Pharmaceuticals underscored its deepening engagement with the rare disease community by serving as Presenting Sponsor of the 2026 Phelan-McDermid Syndrome Foundation Family Conference in Colorado, where executives highlighted progress on NN...
Neuren Set for Major EU Milestone as EMA Backs DAYBU for Rett Syndrome
Jun 28, 2026
Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has secured a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending EU marketing authorisation for DAYBU (trofinetide) t...
Neuren Pharmaceuticals Seeks ASX Quotation for 450,000 New Shares
Jun 18, 2026
Neuren Pharmaceuticals has applied to the ASX for quotation of 450,000 new ordinary fully paid shares, expanding its listed securities on the Australian market. The additional shares, issued on June 18, 2026, modestly increase the company’s ...
Neuren Issues 360,000 Unquoted Shares Under Employee Incentive Scheme
Jun 1, 2026
Neuren Pharmaceuticals has notified the market of the issue of 360,000 new unquoted securities under its employee share scheme, dated May 27, 2026. The securities are subject to transfer restrictions and will not be quoted on the ASX until those r...
Neuren Investors Back Board and CEO Options but Reject Constitution Changes
May 27, 2026
Shareholders of Neuren Pharmaceuticals have backed the re-election of director Joe Basile and approved the company’s auditor remuneration at its 2026 annual general meeting, with both resolutions passing by comfortable margins. Investors als...
Neuren Leverages DAYBUE Windfall to Drive NNZ-2591 Phase 3 Push in Rare Neurological Disorders
May 27, 2026
Neuren reported strong financial performance for 2025, underpinned by DAYBUE royalties that drove a A$30 million profit, A$65 million in royalty income, and a cash position of A$296 million, giving the company substantial resources to fund its gro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.